

### Developing Predictive Bioactivity Signatures from ToxCast's HTS Data

TestSmart DNT 2 Conference – Washington DC, November 12-14 2008

UNITED STATES ENVIRONMENTAL PROTECTION AGENCY COMPUTATIO TOXICOL


Co-authors: David Dix, Keith Houck, Matt Martin, David Reif and Richard Judson

Office of Research and Development National Center for Computational Toxicology


November 13, 2008



#### A Dream from TestSmart 1







### **Future of Toxicity Testing**

#### **POLICY**FORUM

ir.

#### TOXICOLOGY **Transforming Environmental Health Protection**

#### Francis S. Collins,1\*† George M. Gray,2\* John R. Bucher3\*

funded a project at the National Research Council (NRC) to develop a long-range vision cology (NCCT). Through these initiatives, for toxicity testing and a strategic plan for NTP and EPA, with the NCGC, are promotimplementing that vision. Both agencies ing the evolution of toxicology from a prewanted future toxicity testing and assessment dominantly observational science at the paradigms to meet evolving regulatory needs. level of disease-specific models in vivo to a stances that need to be tested and how to incorporate recent advances in molecular toxicol- anism-based, biological observations in ogy, computational sciences, and information technology; to rely increasingly on human as efficiency in design and costs (1-5). In response, the NRC Committee on Toxicity to result in adverse health effects (7). HTS Testing and Assessment of Environmental Agents produced two reports that reviewed for drug development, and screening of current toxicity testing, identified key issues. and developed a vision and implementation strategy to create a major shift in the assess-ment of chemical hazard and risk (6, 7). Although the NRC reports have laid out a solid theoretical rationale, comprehensive and rigorously gathered data (and comparisons with historical animal data) will determine whether the hypothesized improvements will be real ized in practice. For this purpose, NTP, EPA, and the National Institutes of Health Chemical Genomics Center (NCGC) (organizations

#### EPA, NCGC, and NTP Joint Activities

In 2004, the NTP released its vision and roadmap for the 21st century (1), which established initiatives to integrate high-

<sup>1</sup>Director, National Human Genome Research Institute (NHGRI), National Institutes of Health, Bethesda, MD 20892: <sup>2</sup>Assistant Administrator for the Office of Research and Development, U.S. Environmental Protection Agency, Washington, DC 20460; <sup>3</sup>Associate Director, U.S. National Toxicology Program, National Institute of Environmental Health Sciences (NIEHS), Research Triangle Park, NC 27709 USA

\*The views expressed here are those of the individual authors and do not necessarily reflect the views and policies of their respective agencies. tAuthor for correspondence. E-mail: francisc@mail.nih.gov


906

15 FEBRUARY 2008 VOL 319 SCIENCE www.sciencemag.org


1-3 studi

n 2005, the U.S. Environmental Protection throughput screening (HTS) and other auto- tion, usually between 2 and 10  $\mu$ M, and toler-Agency (EPA), with support from the U.S. National Toxicology Program (NTP), program. In 2005, the EPA established the the EPA, NCGC, and NTP combined effort, National Center for Computational Toxiall compounds are tested at as many as 15 concentrations, generally ranging from ~5 nM to ~100 µM, to generate a concentrationresponse curve (9). This approach is highly reproducible, produces significantly lower false-positive and false-negative rates than Challenges include the large numbers of sub- predominantly predictive science focused the traditional HTS methods (9), and facilion broad inclusion of target-specific, mechtates multiassay comparisons. Finally, an informatics platform has been built to comvitro (1, 4) (see figure, below). Toxicity pathways. In vitro and in vivo responses after chemical exposure expected methods are a primary means of discovery

pare results among HTS screens; this is being expanded to allow comparisons with opposed to animal data; and to offer increased tools are being used to identify cellular historical toxicologic NTP and EPA data (http://ncgc.nih.gov/pub/openhts). HTS data collected by EPA and NTP, as well as by the NCGC and other Molecular Libraries Initiative centers (http://mli.nih.gov/), are >100.000 compounds per day is routine (8). being made publicly available through Web-However, drug-discovery HTS methods trabased databases [e.g., PubChem (http:// ditionally test compounds at one concentrapubchem.ncbi.nlm.nih.gov)]. In addition.



#### We propose a shift from primarily in vivo animal studies to in vitro assays, in vivo assays with lower organisms, and computational modeling for toxicity assessments





EPAs Contribution: The ToxCast Research Program

Office of Research and Development National Center for Computational Toxicology

www.epa.gov/ncct/toxcast


2



## Change Needed Because .....

#### **Too Many Chemicals**

#### Too High a Cost



#### ...and not enough data.

Office of Research and Development National Center for Computational Toxicology

Judson, et al EHP submitted



# ToxCast<sup>™</sup> Background

- Research program of EPA's National Center for Computational Toxicology
- Addresses chemical screening and prioritization needs for pesticidal inerts, anti-microbials, CCLs, HPVs and MPVs
- Comprehensive use of HTS technologies to generate biological fingerprints and predictive signatures
- Coordinated with NTP and NHGRI/NCGC via Tox21
- Committed to stakeholder involvement and public release of data
  - Communities of Practice- Chemical Prioritization; Exposure
  - NCCT website- http://www.epa.gov/ncct/toxcast
  - ACToR- Aggregated Computational Toxicology Resource

http://www.epa.gov/actor/





# **Implications for Success**

•Hazard Identification •Closing Data Gaps •Reductions in Cost •Hypothesis Generation •Reduced Animal Usage

•Ancillary Applications •Mixtures •Chirals •Nanomaterials •Green Chemistry •Lot variations

•Risk Assessment •Providing MOA(s) •Targeted Testing •Identifying Susceptible Populations



•Find the Toxicity Pathways •Hepato vs developmental nuerotoxicity

### •Obtain HTS Assays for Them • Including metabolic capability

## Screen Chemical Libraries

Coverage of p-chem properties


#### •Link Results to in vivo Effects • Gold standard and dosimetry



### **Phased Development of ToxCast**

Phase	Number of Chemicals	Chemical Criteria	Purpose	Number of Assays	Cost per Chemical	Target Date
la	320	Data Rich (pesticides)	Signature Development	552	\$20k	FY08 <sup>1</sup>
lb	15	Nanomaterials	Pilot	166	\$10K	FY09
lla	>300	Data Rich Chemicals	Validation	>400	~\$20-25k	FY09
llb	>100	Known Human Toxicants	Extrapolation	>400	~\$20-25k	FY09
lic	>300	Expanded Structure and Use Diversity	Extension	>400	~\$20-25k	FY10
lld	>12	Nanomaterials	PMN	>200	~\$15-20K	FY09-10
111	Thousands	Data poor	Reducing to Practice	>300	~\$15-20k	FY11-12


<sup>1</sup>Initiated April 2007 7



Office of Research and Development National Center for Computational Toxicology




#### **Physical-Chemical Properties**







#### >\$1B in Toxicology Now Stored in ToxRefDB




Office of Research and Development National Center for Computational Toxicology Martin, et al *EHP*, *in press* 10























Martin et al, ToxSci, submitted



Office of Research and Development National Center for Computational Toxicology




Activity (% of Control)

201 Assays




#### **NovaScreen Descriptive Statistics (30% Cutoff)**






#### SOME NEUROTRANSMITTER TARGETS







### **Transcription Factor Activity Profiling**

#### **Cis-Factorial<sup>TM</sup> Biosensors**






# Trans-Factorial<sup>TM</sup> Biosensors



Office of Research and Development National Center for Computational Toxicology 24 nuclear receptors

attagene


The Home of TFomics™





#### **ToxCast Phase I Assays/Datasets/Publications**


- ToxCast 1.0 (April, 2007)
  - Enzyme inhibition/receptor binding HTS (Novascreen)
- MR/transcription factors (Attagene, NCGC)
- 🛨 Cellular impedance (ACEA)
- Complex cell interactions (BioSeek)
- ★ Hepatocelluar HCS (Cellumen)
  - Hepatic, renal and airway cytotoxicity (IVAL)
  - In vitro hepatogenomics (IVAL, Expression Analysis)
  - Zebrafish developmental toxicity (Phylonix)
- ToxCast 1.1 (January, 2008)
  - Neurite outgrowth HCS (NHEERL)
  - Cell proliferation (NHEERL)
  - Zebrafish developmental toxicity (NHEERL)
- ToxCast 1.2 (June, 2008)
- $\star$  NR Activation and translocation (CellzDirect)
- ★ HTS Genotoxicity (Gentronix)
  - Organ toxicity; dosimetry (Hamner Institutes)
  - Toxicity and signaling pathways (Invitrogen)
  - C. elegans WormTox (NIEHS)
  - Gene markers from microscale cultured hepatocytes (MIT)
- $\star$  3D Cellular microarray with metabolism (Solidus)
  - Zebrafish vascular/cardiotoxicity (Zygogen)
  - HTS stress response (NHEERL+NCGC)

21 Assay Sources >550 Endpoints












# A High Throughput Vision for the Source to Outcome Continuum







- The international community needs better predictive tools for assessing the hazards and risks of chemicals
- It is technically feasible to collect bioactivity data on virtually all chemicals of potential concern
- ToxCast is providing a proof of concept for obtaining predictive, broad-based spectra of bioactivity
- A critical need remains the elucidation of the majority of key biological processes involved in toxic responses
- The time is right to rapidly move this field along

# Sepan ToxCast Website: www.epa.gov/ncct/toxcast

#### **National Center for Computational Toxicology**

 Contact Us
 Search:
 O All EPA
 ● This Area
 Go

 You are here:
 EPA Home
 > National Center for Computational Toxicology
 > ToxCast™ Program

#### ToxCast<sup>™</sup> Program Predicting Hazard, Characterizing Toxicity Pathways, and Prioritizing the Toxicity Testing of Environmental Chemicals

#### Introduction

In 2007, EPA launched ToxCast<sup>™</sup> in order to develop a cost-effective approach for prioritizing the toxicity testing of large numbers of chemicals in a short period of time. Using data from state-of-the-art high throughput screening (HTS) bioassays developed in the pharmaceutical industry, ToxCast<sup>™</sup> is building computational models to forecast the potential human toxicity of chemicals. These hazard predictions will provide EPA regulatory programs with science-based information helpful in prioritizing chemicals for more detailed toxicological evaluations, and lead to more efficient use of animal testing.

In its first phase, ToxCast<sup>™</sup> is profiling over 300 well-characterized chemicals (primarily pesticides) in over 400 HTS endpoints. These endpoints include biochemical assays of protein function, cell-based transcriptional reporter assays, multi-cell interaction assays, transcriptomics on primary cell cultures, and developmental assays in zebrafish embryos. Almost all of the compounds being examined in Phase 1 of ToxCast<sup>™</sup> have been tested in traditional toxicology tests, including developmental toxicity, multi-generation studies, and sub-chronic and chronic rodent bioassays. ToxRefDB, a relational database being created to house this information, will contain nearly \$1B worth of toxicity studies in animals when completed. ToxRefDB is integrated into a more comprehensive data management system developed by NCCT called ACTOR (Aggregated Computational Toxicology Resource), that manages the large-scale datasets of ToxCast<sup>™</sup>.

ToxCast<sup>™</sup> Navigation Introduction ToxCast<sup>™</sup> Chemicals ToxCast<sup>™</sup> Assays ToxCast<sup>™</sup> Assays ToxCast<sup>™</sup> Information Management ToxCast<sup>™</sup> Partnerships ToxCast<sup>™</sup> Partnerships ToxCast<sup>™</sup> Presentations ToxCast<sup>™</sup> Publications ToxCast<sup>™</sup> News

ACTOR is comprised of several independent data repositories linked to a common database of chemical structures and properties, and to tools for development of predictive HTS and genomic bioactivity signatures that strongly correlate with specific toxicity endpoints from ToxRefDB. These ToxCast<sup>™</sup> signatures will be defined and evaluated by their ability to predict outcomes from existing mammalian toxicity testing, and identify toxicity pathways that are relevant to human health effects.

The second phase of ToxCast<sup>™</sup> will screen additional compounds representing broader chemical structure and use classes, in order to evaluate the predictive bioactivity signatures developed in Phase I. Following successful conclusion of Phases I and II, ToxCast<sup>™</sup> will provide EPA regulatory programs an efficient tool for rapidly and efficiently screening compounds and prioritizing further toxicity testing.